Role of serum CTRP3 and Metrnl in the diagnosis of type 2 diabetes mellitus complicated with microvascular lesions

doi:10.3969/j.issn.1673-8640.2026.09.007

Abstract

Abstract:

Objective To investigate the role of serum C1q tumor necrosis factor-related protein 3（CTRP3）and meteorin-like protein（Metrnl）in the diagnosis of type 2 diabetes mellitus（T2DM）complicated with microvascular lesions. Methods A total of 215 patients with T2DM （T2DM group） and 215 healthy subjects （healthy control group） were enrolled from Kailuan General Hospital from August 2021 to January 2024. T2DM patients were classified into lesion group（104 cases）and non-lesion group（111 cases）based on whether they had microvascular lesions. The clinical data were collected，and serum CTRP3 and Metrnl levels were determined. Multivariate Logistic regression analysis was used to evaluate the influencing factors of microvascular lesions in T2DM patients. Receiver operating characteristic （ROC） curve was used to evaluate the efficacy of serum CTRP3 and Metrnl in diagnosing microvascular lesions in T2DM patients. Results The serum CTRP3 and Metrnl levels in T2DM group were lower than those in healthy control group （P<0.001），and there was no statistical significance in the other indicators between the 2 groups（P>0.05）. Compared with non-lesion group，the serum CTRP3，Metrnl and high-density lipoprotein cholesterol（HDL-C）levels in lesion group were decreased（P<0.001），while the serum total cholesterol（TC），triglyceride（TG）and low-density lipoprotein cholesterol（LDL-C）levels were increased （P<0.001）. There was no statistical significance in the other indicators between the 2 groups（P>0.05）. Decreased serum CTRP3 and Metrnl levels were risk factors for microvascular lesions in T2DM patients [odds ratios（OR）were 0.276 and 0.124，95% confidence intervals（CI）were 0.138-0.552 and 0.055-0.278，P<0.001]. The areas under curves （AUC） of single and combined determinations of serum CTRP3 and Metrnl for diagnosing microvascular lesions in T2DM patients were 0.816，0.810 and 0.882，respectively. Conclusions The combined determination of serum CTRP3 and Metrnl plays a role in the diagnosis of microvascular lesions in T2DM.

Key words: C1q tumor necrosis factor-related protein 3, Meteorin-like protein, Type 2 diabetes mellitus, Microvascular lesion

CLC Number:

R446.1

WANG Qian, CHU Lulu, ZHANG Wenting, WANG Ya. Role of serum CTRP3 and Metrnl in the diagnosis of type 2 diabetes mellitus complicated with microvascular lesions[J]. Laboratory Medicine, 2026, 41(9): 867-871.

Figures/Tables 5

References 20

[1]	张爱民, 殷悦, 秦莉, 等. 血清sd-LDL-C与2型糖尿病患者冠状动脉病变严重程度和心血管事件发生风险的相关性[J]. 检验医学, 2025, 40(1):66-72. DOI
[2]	Yan Y, Wu T, Zhang M, et al. Prevalence,awareness and control of type 2 diabetes mellitus and risk factors in Chinese elderly population[J]. BMC Public Health, 2022, 22(1):1382. DOI
[3]	Goldney J, Sargeant J A, Davies M J. Incretins and microvascular complications of diabetes:neuropathy,nephropathy,retinopathy and microangiopathy[J]. Diabetologia, 2023, 66(10):1832-1845. DOI
[4]	Liu D, Cui X, Lu R, et al. CTRP3 is a coronary artery calcification biomarker and protects against vascular calcification by inhibiting β-catenin nuclear translocation to prevent vascular smooth muscle cell osteogenic differentiation[J]. J Cardiol, 2022, 79(4):551-558. DOI URL
[5]	罗千军, 陈传绮, 鄢燕琼. 血清LCN2、CTRP3在糖尿病视网膜病变中的水平及其临床意义[J]. 标记免疫分析与临床, 2021, 28(1):85-89.
[6]	Lu Q B, Ding Y, Liu Y, et al. Metrnl ameliorates diabetic cardiomyopathy via inactivation of cGAS/STING signaling dependent on LKB1/AMPK/ULK1-mediated autophagy[J]. J Adv Res, 2023, 51:161-179. DOI URL
[7]	苗素芳, 张维娜, 张姣姣. 血清Zonulin和Metrnl水平与糖尿病肾病患者病情及预后的关系[J]. 新疆医科大学学报, 2023, 46(11):1513-1518.
[8]	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4):315-409.
[9]	Gross J L, De Azevedo M J, Silveiro S P, et al. Diabetic nephropathy:diagnosis,prevention,and treatment[J]. Diabetes Care, 2005, 28(1):164-176. DOI URL
[10]	中华医学会眼科学会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2014年)[J]. 中华眼科杂志, 2014, 50(11):851-865.
[11]	Pop-busui R, Boulton A J, Feldman E L, et al. Diabetic neuropathy:a position statement by the American Diabetes Association[J]. Diabetes Care, 2017, 40(1):136-154. DOI PMID
[12]	Takahashi K, Mizukami H, Osonoi S, et al. Islet microangiopathy and augmented β-cell loss in Japanese non-obese type 2 diabetes patients who died of acute myocardial infarction[J]. J Diabetes Investig, 2021, 12(12):2149-2161. DOI URL
[13]	王海燕, 张永红. 糖尿病微血管病变发病机制研究进展[J]. 河北医科大学学报, 2024, 45(5):585-589.
[14]	李倩, 王硕, 陈亚荣, 等. 糖尿病合并骨质疏松患者血清C1q/肿瘤坏死因子相关蛋白3的表达及临床意义[J]. 实用临床医药杂志, 2023, 27(12):57-62.
[15]	Guo B, Zhuang T, Xu F, et al. New insights into implications of CTRP3 in obesity,metabolic dysfunction,and cardiovascular diseases:potential of therapeutic interventions[J]. Front Physiol, 2020, 11:570270. DOI URL
[16]	Moradi N, Fadaei R, Khamseh M E, et al. Serum levels of CTRP3 in diabetic nephropathy and its relationship with insulin resistance and kidney function[J]. PLoS One, 2019, 14(4):e0215617. DOI URL
[17]	Zhou Y, Liu L, Jin B, et al. Metrnl alleviates lipid accumulation by modulating mitochondrial homeostasis in diabetic nephropathy[J]. Diabetes, 2023, 72(5):611-626. DOI URL
[18]	Liu M, Gao X, Tian Y, et al. Serum Metrnl is decreased in metabolic dysfunction-associated fatty liver disease:a case-control study[J]. Diabetes Metab Syndr Obes, 2024, 17:533-543. DOI URL
[19]	AlKhairi I, Cherian P, Abu-farha M, et al. Increased expression of meteorin-like hormone in type 2 diabetes and obesity and its association with irisin[J]. Cells, 2019, 8(10):1283. DOI URL
[20]	Miao Z W, Hu W J, Li Z Y, et al. Involvement of the secreted protein Metrnl in human diseases[J]. Acta Pharmacol Sin, 2020, 41(12):1525-1530. DOI

组别	例数	性别		年龄/岁	BMI/ （kg·m^-2）	吸烟史		饮酒史
组别	例数	男/例	女/例	年龄/岁	BMI/ （kg·m^-2）	是/例	否/例	是/例	否/例
T2DM组	215	110	105	57.17±7.01	22.52±3.33	86	129	81	134
正常对照组	215	118	97	56.57±8.04	22.37±2.76	78	137	75	140
统计值		0.598		0.825	0.509	0.631		0.362
P值		0.440		0.410	0.611	0.427		0.547
组别	收缩压/kPa		舒张压/kPa	居住地		CTRP3/（ng·mL^-1）			Metrnl/（ng·mL^-1）
组别	收缩压/kPa		舒张压/kPa	城市/例	农村/例	CTRP3/（ng·mL^-1）			Metrnl/（ng·mL^-1）
T2DM组	16.77±2.38		11.29±0.80	102	113	116.12±22.10			90.11±12.12
正常对照组	16.61±2.49		11.17±0.78	114	101	175.43±32.51			121.46±18.43
统计值	0.681		1.575	1.340		22.123			20.840
P值	0.496		0.116	0.247		<0.001			<0.001

组别	例数	性别		年龄/岁	BMI/ （kg·m^-2）	吸烟史		饮酒史
组别	例数	男/例	女/例	年龄/岁	BMI/ （kg·m^-2）	是/例	否/例	是/例	否/例
T2DM组	215	110	105	57.17±7.01	22.52±3.33	86	129	81	134
正常对照组	215	118	97	56.57±8.04	22.37±2.76	78	137	75	140
统计值		0.598		0.825	0.509	0.631		0.362
P值		0.440		0.410	0.611	0.427		0.547
组别	收缩压/kPa		舒张压/kPa	居住地		CTRP3/（ng·mL^-1）			Metrnl/（ng·mL^-1）
组别	收缩压/kPa		舒张压/kPa	城市/例	农村/例	CTRP3/（ng·mL^-1）			Metrnl/（ng·mL^-1）
T2DM组	16.77±2.38		11.29±0.80	102	113	116.12±22.10			90.11±12.12
正常对照组	16.61±2.49		11.17±0.78	114	101	175.43±32.51			121.46±18.43
统计值	0.681		1.575	1.340		22.123			20.840
P值	0.496		0.116	0.247		<0.001			<0.001

组别	例数	性别				年龄/岁		BMI/ （kg·m^-2）	吸烟史			饮酒史
组别	例数	男/例	女/例			年龄/岁		BMI/ （kg·m^-2）	是/例		否/例	是/例		否/例
病变组	104	48	56			57.87±6.87		22.45±3.57	45		59	42		62
非病变组	111	62	49			56.52±7.15		22.58±3.11	41		70	39		72
统计值		2.023				1.410		0.285	0.897			0.630
P值		0.155				0.160		0.776	0.344			0.427
组别	收缩压/kPa			舒张压/kPa		居住地			CTRP3/（ng·mL^-1）					Metrnl/（ng·mL^-1）
组别	收缩压/kPa			舒张压/kPa		城市/例		农村/例	CTRP3/（ng·mL^-1）					Metrnl/（ng·mL^-1）
病变组	16.99±2.44			11.37±0.87		54		50	102.28±18.77					82.46±10.24
非病变组	16.56±2.33			11.22±0.73		48		63	129.08±25.22					97.27±13.88
统计值	1.322			1.373		1.622			8.792					8.855
P值	0.188			0.171		0.203			<0.001					<0.001
组别	糖尿病病程/年				TG/（mmol·L^-1）		LDL-C/（mmol·L^-1）			TC/（mmol·L^-1）			HDL-C/（mmol·L^-1）
病变组	10.42±3.22				2.84±0.33		3.64±0.48			5.72±1.11			1.11±0.35
非病变组	10.25±2.87				2.13±0.35		2.96±0.41			4.86±0.97			1.32±0.38
统计值	0.409				15.280		11.191			6.059			4.207
P值	0.683				<0.001		<0.001			<0.001			<0.001

组别	例数	性别				年龄/岁		BMI/ （kg·m^-2）	吸烟史			饮酒史
组别	例数	男/例	女/例			年龄/岁		BMI/ （kg·m^-2）	是/例		否/例	是/例		否/例
病变组	104	48	56			57.87±6.87		22.45±3.57	45		59	42		62
非病变组	111	62	49			56.52±7.15		22.58±3.11	41		70	39		72
统计值		2.023				1.410		0.285	0.897			0.630
P值		0.155				0.160		0.776	0.344			0.427
组别	收缩压/kPa			舒张压/kPa		居住地			CTRP3/（ng·mL^-1）					Metrnl/（ng·mL^-1）
组别	收缩压/kPa			舒张压/kPa		城市/例		农村/例	CTRP3/（ng·mL^-1）					Metrnl/（ng·mL^-1）
病变组	16.99±2.44			11.37±0.87		54		50	102.28±18.77					82.46±10.24
非病变组	16.56±2.33			11.22±0.73		48		63	129.08±25.22					97.27±13.88
统计值	1.322			1.373		1.622			8.792					8.855
P值	0.188			0.171		0.203			<0.001					<0.001
组别	糖尿病病程/年				TG/（mmol·L^-1）		LDL-C/（mmol·L^-1）			TC/（mmol·L^-1）			HDL-C/（mmol·L^-1）
病变组	10.42±3.22				2.84±0.33		3.64±0.48			5.72±1.11			1.11±0.35
非病变组	10.25±2.87				2.13±0.35		2.96±0.41			4.86±0.97			1.32±0.38
统计值	0.409				15.280		11.191			6.059			4.207
P值	0.683				<0.001		<0.001			<0.001			<0.001

项目	β值	标准误	Wald值	P值	OR值（95%CI）
CTRP3	-1.287	0.354	13.225	<0.001	0.276（0.138~0.552）
Metrnl	-2.087	0.412	25.671	<0.001	0.124（0.055~0.278）
TG	0.291	0.543	0.288	0.592	1.338（0.462~3.879）
LDL-C	0.726	0.627	1.341	0.247	2.067（0.605~7.064）
TC	0.455	0.276	2.716	0.099	1.576（0.918~2.707）
HDL-C	-0.171	0.488	0.122	0.726	0.843（0.324~2.194）